NO308509B1 - FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse - Google Patents
FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse Download PDFInfo
- Publication number
- NO308509B1 NO308509B1 NO923542A NO923542A NO308509B1 NO 308509 B1 NO308509 B1 NO 308509B1 NO 923542 A NO923542 A NO 923542A NO 923542 A NO923542 A NO 923542A NO 308509 B1 NO308509 B1 NO 308509B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- idiotype
- making
- protein
- dendritic cells
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 24
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 15
- 230000028993 immune response Effects 0.000 title claims abstract description 13
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 12
- 241000124008 Mammalia Species 0.000 title claims abstract description 7
- 230000001939 inductive effect Effects 0.000 title claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 229940079593 drug Drugs 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title claims description 8
- 210000000170 cell membrane Anatomy 0.000 title claims description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 48
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 19
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 29
- 238000000338 in vitro Methods 0.000 claims description 16
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 abstract description 22
- 238000002649 immunization Methods 0.000 abstract description 22
- 230000036039 immunity Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 9
- 230000003302 anti-idiotype Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000007660 Residual Neoplasm Diseases 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 108010058936 Cohn fraction V Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000005717 Myeloma Proteins Human genes 0.000 description 1
- 108010045503 Myeloma Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/493,511 US20030072751A1 (en) | 1990-03-14 | 1990-03-14 | Idiotypic vaccination against b cell lymphoma |
| PCT/US1991/001683 WO1991013632A1 (en) | 1990-03-14 | 1991-03-13 | Idiotypic vaccination against b cell lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO923542D0 NO923542D0 (no) | 1992-09-11 |
| NO923542L NO923542L (no) | 1992-09-11 |
| NO308509B1 true NO308509B1 (no) | 2000-09-25 |
Family
ID=23960532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO923542A NO308509B1 (no) | 1990-03-14 | 1992-09-11 | FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030072751A1 (fi) |
| EP (1) | EP0521897B1 (fi) |
| JP (1) | JP2735947B2 (fi) |
| AT (1) | ATE124265T1 (fi) |
| AU (1) | AU645552B2 (fi) |
| CA (1) | CA2078235C (fi) |
| DE (1) | DE69110877T2 (fi) |
| DK (1) | DK0521897T3 (fi) |
| ES (1) | ES2074268T3 (fi) |
| FI (1) | FI105452B (fi) |
| NO (1) | NO308509B1 (fi) |
| WO (1) | WO1991013632A1 (fi) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004807A (en) * | 1992-03-30 | 1999-12-21 | Schering Corporation | In vitro generation of human dendritic cells |
| CA2133409C (en) * | 1992-04-01 | 2011-05-24 | Ralph M. Steinman | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| AU687733B2 (en) * | 1992-04-01 | 1998-03-05 | Rockefeller University, The | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| EP1421947A1 (en) * | 1992-07-22 | 2004-05-26 | The Trustees Of Princeton University | p53 vaccine |
| DE69331703D1 (de) * | 1992-08-21 | 2002-04-18 | Us Gov Health & Human Serv | B-lymphomazellinie und antigen |
| US5651993A (en) | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
| CA2158281A1 (en) * | 1993-03-15 | 1994-09-29 | Jay A. Berzofsky | Peptide coated dendritic cells as immunogens |
| WO1995034638A1 (en) * | 1994-06-14 | 1995-12-21 | The Board Of Trustees Of Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| US6340981B1 (en) | 1997-06-30 | 2002-01-22 | Sun Microsystems, Inc. | Method and apparatus for stroke substitution |
| US6010905A (en) * | 1995-01-27 | 2000-01-04 | The United States Of America As Represented By The Department Of Health & Human Services | Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| WO1997022349A1 (en) * | 1995-12-20 | 1997-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
| ATE428769T1 (de) | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| CA2321093A1 (en) | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| US8313945B2 (en) | 1999-04-20 | 2012-11-20 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| CA2368855C (en) | 1999-04-20 | 2012-05-29 | Richard Leslie Edelson | Differentiation of monocytes into functional dendritic cells |
| US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| AT409086B (de) * | 1999-11-16 | 2002-05-27 | Igeneon Krebs Immuntherapie | Neue verwendung von antikörpern als impfstoffe |
| US8524495B2 (en) | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
-
1990
- 1990-03-14 US US07/493,511 patent/US20030072751A1/en not_active Abandoned
-
1991
- 1991-03-13 DE DE69110877T patent/DE69110877T2/de not_active Expired - Fee Related
- 1991-03-13 WO PCT/US1991/001683 patent/WO1991013632A1/en active IP Right Grant
- 1991-03-13 JP JP3506222A patent/JP2735947B2/ja not_active Expired - Lifetime
- 1991-03-13 CA CA002078235A patent/CA2078235C/en not_active Expired - Fee Related
- 1991-03-13 EP EP91905685A patent/EP0521897B1/en not_active Expired - Lifetime
- 1991-03-13 DK DK91905685.3T patent/DK0521897T3/da active
- 1991-03-13 ES ES91905685T patent/ES2074268T3/es not_active Expired - Lifetime
- 1991-03-13 AU AU74886/91A patent/AU645552B2/en not_active Ceased
- 1991-03-13 AT AT91905685T patent/ATE124265T1/de not_active IP Right Cessation
-
1992
- 1992-09-11 FI FI924082A patent/FI105452B/fi not_active IP Right Cessation
- 1992-09-11 NO NO923542A patent/NO308509B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05507905A (ja) | 1993-11-11 |
| CA2078235A1 (en) | 1991-09-15 |
| EP0521897B1 (en) | 1995-06-28 |
| AU7488691A (en) | 1991-10-10 |
| ES2074268T3 (es) | 1995-09-01 |
| FI924082A (fi) | 1992-09-11 |
| DE69110877D1 (de) | 1995-08-03 |
| EP0521897A1 (en) | 1993-01-13 |
| CA2078235C (en) | 2004-01-20 |
| JP2735947B2 (ja) | 1998-04-02 |
| FI924082A0 (fi) | 1992-09-11 |
| US20030072751A1 (en) | 2003-04-17 |
| NO923542D0 (no) | 1992-09-11 |
| AU645552B2 (en) | 1994-01-20 |
| DE69110877T2 (de) | 1995-11-16 |
| ATE124265T1 (de) | 1995-07-15 |
| NO923542L (no) | 1992-09-11 |
| WO1991013632A1 (en) | 1991-09-19 |
| FI105452B (fi) | 2000-08-31 |
| DK0521897T3 (da) | 1995-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO308509B1 (no) | FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse | |
| Tada et al. | Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia-and Ia+ helper T cells. | |
| Leclerc et al. | A synthetic vaccine constructed by copolymerization of B and T cell determinants | |
| Taniguchi et al. | Cellular consequences in the suppression of antibody response by the antigen-specific T-cell factor. | |
| US20090117135A1 (en) | Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies | |
| NO319013B1 (no) | Vaksine omfattende type I overflateantigener fra Staphylococcus epidermidis, samt hyperimmune globuliner og antistoff rettet mot type I-overflateantigenet. | |
| CN101790382A (zh) | 独特型疫苗 | |
| Ramalho‐Pinto et al. | Murine Schistosomiasis mansoni: anti‐schistosomula antibodies and the IgG subclasses involved in the complement‐and eosinophilmediated killing of schistosomula in vitro | |
| Francotte et al. | Enhancement of antibody response by mouse dendritic cells pulsed with tobacco mosaic virus or with rabbit antiidiotypic antibodies raised against a private rabbit idiotype. | |
| Dorfman | The optimal technological approach to the development of human hybridomas | |
| WO1999008705A1 (en) | Capsular polysaccharides from enterococci | |
| Manches et al. | Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. | |
| Prager et al. | Immunological stimulation with modified lymphoma cells in a minimally responsive tumor-host system | |
| Hendriksen et al. | Production of polyclonal and monoclonal antibodies | |
| CA2176738C (en) | Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor | |
| US20040009195A1 (en) | Modified sialic acid vaccines | |
| Campbell | Production and purification of antibodies | |
| US20020122809A1 (en) | Capsular polysaccharides from enterococci | |
| Ding et al. | Activation of helper T cells by immune complexes | |
| Kodama et al. | Induction of IgM memory with RNA from the spleens of immunized mice. | |
| EP1474682A2 (en) | Production of human antibodies in immunodeficient, non-human, mammalian hosts | |
| RU2063245C1 (ru) | Способ получения антител для производства диагностических препаратов вируса клещевого энцефалита | |
| Kakimoto et al. | Different types of antigen-presenting cells affect the induction of experimental autoimmune arthritis | |
| JPH07116057B2 (ja) | 免疫増強剤及び強化抗原 | |
| Morris | Developmental acquisition of B lymphocyte antigen presentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |